Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma

SIMPLE SUMMARY: Cholangiocarcinoma constitutes around 3% of gastrointestinal cancers, and mortality from this cancer has been rising in the recent decades. Many cases of cholangiocarcinoma are unfortunately discovered in their advanced stages which cannot be treated with surgical resection alone. Ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Su Min, Esmail, Abdullah, Raza, Ali, Dacha, Sunil, Abdelrahim, Maen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179455/
https://www.ncbi.nlm.nih.gov/pubmed/35681621
http://dx.doi.org/10.3390/cancers14112641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179455/
https://www.ncbi.nlm.nih.gov/pubmed/35681621
http://dx.doi.org/10.3390/cancers14112641

Ejemplares similares